> Cassiopea posted more positive data on its pipeline. On Monday, the company reported interim data on clascoterone in androgenetic alopecia. Days later, Cassiopea added phase 2 genital wart data to its list of recent readouts. Release I More
> Takeda struck a deal to assess the feasibility of leon-nanodrugs’ MicroJet Reactor. Statement
> Silence Therapeutics named David Horn Solomon as its CEO. Solomon ran Zealand Pharma from 2008 to 2015. Release
> Poxel posted data from a phase 1b NASH trial. The French biotech will now move the candidate into phase 2a. Statement
> Adaptimmune received clearance for dose escalation in its MAGE-A10 pilot studies. Release